PFE Stock: Buy or Sell? Price Target & Forecast

PFE Pfizer Inc As of Sep 15, 2026

$27.72

Mega-cap pharma trading at elevated backward P/E; forward multiple, dividend yield, and insider buying suggest stabilization as headwinds ease.

Setup: Value / Income with Recovery Optionality Confidence: 65 Horizon: 3–6 months Risk: Medium Category: Large Cap Pharmaceuticals

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals PFE's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Forward P/E of 20.4x vs trailing 36.5x signals earnings inflection ahead. 5.4% dividend yield attracts income investors. Insider buying (74 buys vs 27 sells, net +1.9M shares) suggests confidence post-headwinds. Pipeline M&A and obesity/cancer focus frame growth catalysts. Stock trading near 52-week midpoint (current 27.72 vs range 23.58–29.21) after near-term bounce.

▼ Bear Case

EPS down 37% YoY; 5Y EPS CAGR negative at -3.5%. Revenue contracted 14.8% YoY, though 5Y growth +8.5%. Payout ratio at 126% unsustainable without earnings recovery. P/B 1.64x vs historical pharma median; valuation not cheap. Quick ratio 0.87 signals tighter liquidity. Forward guide execution risk remains.

Valuation

Mixed — Overvalued on trailing; Fair on forward with recovery assumption. — score 62/100

Trailing P/E 36.5x is inflated by depressed earnings base. Forward P/E 20.4x and P/S 2.5x align with large-cap pharma peers IF earnings inflection materializes. P/B 1.64x sits at sector median. EV/EBITDA 15.5x reasonable for 12–15% net margin target. Key risk: forward assumes earnings recovery not yet visible.

Technical Levels

Support · $26.50 (Recent consolidation floor; psychological 52w midpoint) · $25.00 (52-week low at 23.58; support zone 24.5–25.5)

Resistance · $29.21 (52-week high; strong resistance) · $31.00 (Target on earnings recovery narrative)

RSI: Not provided by provider; recommend checking external charting.

Financial Health

Score 64/100. Large-cap balance sheet; current ratio 1.16 and quick 0.87 suggest adequate but tightening working capital. Payout >125% is the red flag — unsustainable without earnings recovery. Enterprise value 220B vs market cap 158B indicates moderate debt load. Monitor next quarterly cash flow for FCF generation.

Catalysts

Q earnings report (next quarter)	Likely within 4–6 weeks; watch for EPS inflection and forward guidance.	High — beat/miss will revalidate (or invalidate) forward P/E assumption. Forward guidance on revenue stabilization and margin recovery critical.
M&A or pipeline advancement (obesity, oncology)	Ongoing; PFE stated Phase 1–2 focus.	Medium-High — early-stage clinical wins or acquisitions would support bull narrative and re-rate multiple upward.
Dividend sustainability reset (if needed)	Would likely coincide with Q earnings or capital allocation review.	High negative if cut; moderate positive if maintained with confidence on EPS recovery.
Competitor clinical outcomes (AZN, LLY, others) and competitive intelligence	Ongoing; recent AZN breast cancer fail creates relative safety narrative for PFE.	Medium — positions PFE favorably in oncology if pipeline advance.

Risk Flags

EPS and revenue contracting YoY; forward recovery unproven. Watch Q earnings for stabilization.

Payout ratio >125% unsustainable; dividend cut risk if EPS doesn't recover.

Quick ratio 0.87 below 1.0; monitor cash generation and debt.

RSI, ROE, ROA, debt-to-equity not provided by provider; valuation gaps limit full picture.

Recent news references 'headwinds easing' but no earnings date; timing of inflection unclear.

See PFE's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock PFE free →

More Analyses

NVDA

AAPL

TSLA

MSFT

AMZN

GOOGL

PFE FAQ

Is PFE a buy right now?

Pfizer Inc's current read is a Value / Income with Recovery Optionality setup with 65 confidence over a 3–6 months horizon. Valuation: Mixed — Overvalued on trailing; Fair on forward with recovery assumption.. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is PFE overvalued?

Mixed — Overvalued on trailing; Fair on forward with recovery assumption. (valuation score 62/100). Trailing P/E 36.5x is inflated by depressed earnings base. Forward P/E 20.4x and P/S 2.5x align with large-cap pharma peers IF earnings inflection materializes. P/B 1.64x sits at sector median. EV/EBITDA 15.5x reasonable for 12–15% net margin target. Key risk: forward assumes earnings recovery not yet visible.

What are the risks of buying PFE?